Welcome, Guest
Username: Password: Remember me
Off Topic on Adult (=regenerative) cell technology, but very much related i.e. pills and drugs of which we do not know if they work
  • Page:
  • 1

TOPIC: Cardiac stem cells may worsen heart failure

Cardiac stem cells may worsen heart failure 19 Dec 2017 09:15 #10819

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2864
  • Thank you received: 204
www.medicalnewstoday.com/articles/317969.php?sr

A few months old but interesting especially since inflammation is something we are supposed to treat quite well.....scrolling beyond the article are a few other stem cell stories as well

Please Log in or Create an account to join the conversation.

Cardiac stem cells may worsen heart failure 19 Dec 2017 10:51 #10820

  • rodney.strongg
  • rodney.strongg's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1363
  • Thank you received: 19

myownhedgefund wrote: www.medicalnewstoday.com/articles/317969.php?sr

A few months old but interesting especially since inflammation is something we are supposed to treat quite well.....scrolling beyond the article are a few other stem cell stories as well


I personally always thought that it would be absolutely stupid to simply take cells from a diseased heart (or other diseased organ) to try to help or cure the same diseased organ - nes pah?

Please Log in or Create an account to join the conversation.

Cardiac stem cells may worsen heart failure 20 Dec 2017 09:02 #10821

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Rodents are not humans- lets start with that and coming out with a rodent study after the cardiospheres science has been already established science for more than 10 years, is lets say- somewhat late in the day and superfluous and at best rather doubtful.

Celyad (formerly Cardio³, already finished their Phase 3 quite some time ago- from their HP:

Cell and gene therapies hold tremendous promise in the area of HF, and Celyad’s C-Cure® has the potential to be both the most efficacious treatment as well as the first cell therapy in the HF market. Based on innovative cardiopoiesis technology developed at the Mayo Clinic, ​C-Cure® therapy has been shown to greatly improve outcomes for patients with HF compared with other clinical options. Further enhancing ​C-Cure®'s efficacy is C-CathezTM, Celyad’s best-in-class cell therapy delivery device.
C-CathezTM improves the efficacy of ​C-Cure® therapy due to significantly higher retention rates compared with competing catheters and better ease of use.

​C-Cure® therapy is well positioned in the HF market as one of the first cell therapies, and the technology is protected by multiple proprietary components. After development at the Mayo Clinic, the ​C-Cure® technology was exclusively licensed to Celyad for clinical development. Additionally, the breakthrough cardiopoiesis platform is backed by a robust patent portfolio, manufacturing expertise, and internal trade secrets unique to Celyad.

CHART-1: European Phase III clinical trial completed

​C-Cure® therapy has undergone testing in one of the first controlled trials of its kind for advanced ischemic HF, CHART-1 (EU Phase III trial). Although the primary endpoint of the randomized trial was not met, a post hoc analysis identified a well-defined subset of patients representing more than 60% of the overall trial population that achieved a clinically meaningful response. Based on the results of CHART-1, a pivotal trial (CHART-2) has been designed to exclusively enroll the key patient subpopulation that will most benefit from ​C-Cure® therapy. Furthermore, CHART-2 will incorporate better dosing regimens, more stringent medical personnel training, and a new FDA-agreed primary endpoint based on CHART-1 results. Importantly, when the new parameters for CHART-2 are applied to CHART-1, those patients had a statistically significantly improved outcome compared with the controls.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.085 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites